SCTX
Scribe Therapeutics Inc. Common Stock (SCTX)
Healthcare • NASDAQ • $31.34+9.31%
- Symbol
- SCTX
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $31.34
- Daily Change
- +9.31%
- Market Cap
- $542.77M
- Trailing P/E
- N/A
- Forward P/E
- -7.93
- 52W High
- $39.60
- 52W Low
- $17.31
- Analyst Target
- $57.00
- Dividend Yield
- N/A
- Beta
- N/A
Scribe Therapeutics Inc. operates as a clinical-stage biotechnology company, focuses on research and developing genetic medicines using CRISPR-based tools to address the root cause of diseases, with a primary focus on cardiometabolic conditions in the United States. The company offers STX-1150 designed to be a single-course in vivo epigenetic silencing treatment targeting the PCSK9 gene; STX-1200 is CRISPR-based gene editing program that aims to offer a permanent solution for patients with elevated Lp(a); and STX-1400 is designed to target and remove the transcriptional start site of the APOC3 gene and strongly reduce mRNA expression. It uses CRISPR-based platforms, such as ELXR, designed for precise, durable epigenetic silencing of genes without changing the underlying DNA sequence; and X…
Company websiteResearch SCTX on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.